PATENT CLAIM ANALYSIS

Application Number: 16139352
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "400000"]

Abstract:
The present invention provides a novel crystalline form of Eluxadoline, Eluxadoline Form APO-I, a co-crystal of Eluxadoline and methyl nicotinate, compositions and processes for the preparation thereof, and the use of this crystalline form in the treatment of opioid-modulated disorders, and in particular, gastrointestinal disorders, including irritable bowel syndrome with diarrhea (IBS-D).

Claim (Index 13):
The pharmaceutical composition of  claim 12 , wherein the pharmaceutical composition is a tablet.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 97.0
- Lexical Diversity: 1.5122
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15827471', '16348720', '12291517', '15745228', '15518895']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7754071338962374
- 35 USC 102 Novelty (BERT): 0.5175954383493684
- Combined Prediction Score: 0.7496259643415505
- Mean Citation Score: 230.815158
- Max Citation Score: 261.1942
- Similarity Product: 152.07152656196357

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test